资助2.5亿美元的Crystalys Therapeutics公司将推出一种新的痛风治疗方法, Crystalys Therapeutics, with $205M in funding, launches to advance a new gout treatment in early human trials.

Crystalys Therapeutics 已启动 2.05 亿美元的资金，以推进一种新的痛风治疗方法的临床试验，针对尿酸积聚引起的疼痛性炎症的根本原因。 Crystalys Therapeutics has launched with $205 million in funding to advance clinical trials for a new gout treatment, targeting the root causes of the painful inflammatory condition caused by uric acid buildup. 投资将支持早期的人体试验,以评估药物的安全性,耐受性和有效性,旨在解决痛风治疗的未满足需求. The investment will support early-stage human trials to assess the drug’s safety, tolerability, and effectiveness, aiming to address unmet needs in gout care. 该公司总部设在弗吉尼亚州Ashburn,是一家私人生物技术公司,侧重于新陈代谢和炎症的新疗法。 The company, based in Ashburn, Virginia, is a private biotech focused on innovative therapies for metabolic and inflammatory diseases.